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In this paper, we investigated the oxidative profile of breast tumors in comparison with their normal adjacent breast tissue. Our
study indicates that breast tumors present enhanced oxidative/nitrosative stress, with concomitant augmented antioxidant capacity
when compared to the adjacent normal breast. These data indicate that breast cancers may be responsible for the induction of a
prooxidant environment in the mammary gland, in association with enhanced TNF-𝛼 and nitric oxide.
1. Introduction
Redox imbalance is a process reported in most of the chronic
diseases [1]. The constant activity of reactive species (RS)
on lipids, DNA, and proteins promotes critical modifications
in cell physiology [2], which can interfere with its normal
functioning under chronic inflammatory conditions, such as
cancer [3].
Cancer cells constantly experience moderate to high
levels of oxidative stress, but curiously moderate to high
oxidative stress does not cause immediate cell death [4].
This fact indicates that cancer cells are able to overcome and
adapt against redox changes. The sustained oxidative stress
promoted during chronic inflammation supports pivotal
events to cancer survival, including most of the hallmarks of
cancer. This fact has been associated with aberrant activation
of transcription factors, induction of protooncogenes, and
cumulative acquisition of mutations, which perpetuates the
genomic instability of cancer cells [5].
Tumors with enhanced proliferative capacity, as breast
cancer, produce high levels of RS during their chronic
cycles of ischemia, reperfusion, and angiogenesis, resulting
in exceeding growth signaling [6]. It is reported that DNA
obtained from breast carcinomas presents greater oxidative
damage than the adjacent nontumoral breast [7], suggesting
that the tumor cells are more exposed to in situ oxidative
stress than the proximal or distant nontumoral tissues. On
the other hand, this fact suggests that cancer can potentially
induce oxidative damage in surrounding normal cells.
Therefore, nontransformed epithelial cells located adja-
cently to the tumoral tissue may experience variable con-
centrations of RS generated by the constitutive activation of
mitogenic pathways arising from surrounding tumor cells
[8]; however, the impact of this event on the homeostasis
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of nontumoral adjacent cells is unclear. What is known so
far is that tumors are “oxidatively stressed” and that in some
extension it could be related with the systemic redox changes
reported in patients bearing breast tumors [9–11].
Although growing evidence highlights the occurrence of
persistent oxidative stress in breast tumors, most of studies
have not focused on reporting the redox modifications of
breast cancer regarding its healthy counterpart tissue and
whether there is a relationship between the tumor oxidative
status and the systemic redox profiling. In this context, we
proposed to map the oxidative and inflammatory profiles of
fresh nonfixed breast tumors and their paired adjacent mam-
mary nontumoral tissue, as well as their respective plasma.
To reach these goals, we designed our analysis employing
high-sensitivity oxidative stress approaches to investigate the
functional redox changes that occurred in tumor microen-
vironment and its correlation with the circulating levels of
proinflammatory/oxidative mediators.
2. Material and Methods
2.1. Study Design. A series of 321 women with breast cancer
were screened from March 2011 to December 2012 at Lon-
drina Cancer Institute, Londrina, Parana´, Brazil. A total of
50 women were included based on the inclusion and exclu-
sion criteria. Inclusion criteria embraced women bearing
unilateral tumor with histopathological diagnosis of primary
ductal infiltrative carcinoma of the breast, before starting
the chemotherapeutic regimen. Exclusion criteria included
current smoking, hepatic, cardiac, or renal dysfunction,
obesity, use of drugs, hypertension, autoimmune disorders,
and diabetes, among other chronic conditions.
Adjacent mammary tissue and tumoral tissue were surgi-
cally resected at the moment of tumor withdrawal according
to standard procedures, before chemotherapy starting. The
adjacent tissue was collected from the most distant point
in relation to the tumoral tissue (3 to 4 cm of distance
from themacroscopic tumor). Adjacent breast was confirmed
as nontumoral by conventional histopathological analysis.
Heparinized bloodwas further collected for analysis. Samples
were kept frozen at −86∘C until analysis, by at most 2 weeks.
All recommendations of the Reporting Recommenda-
tions for TumorMarker Prognostic Studies (REMARK) crite-
ria [12] were followed throughout this study regarding patient
selection, assays performance, and data analysis. Institutional
board previously approved all practice and all participants
signed informed consent terms. This study is in accordance
with the ethical principles for medical research involving
human subjects from the Declaration of Helsinki.
Clinicopathological data of cancer patients was collected
from medical records and included age at diagnosis, TNM
staging, tumor histological type, histological tumor grade,
lymph nodal status, tumor size, and presence of distant
metastasis.
2.2. Immunohistochemical Labeling for Nitrotyrosine (NT).
Nitrotyrosine (NT) is a residue formed by the action of
peroxynitrite (derived from the reaction of nitric oxide
and superoxide anion) on proteins. Paraffin-embedded sec-
tions were heated (30min, 65∘C), deparaffinized, and rehy-
drated. Sections were treated at room temperature with 2%
bovine serum albumin and incubated overnight at 4∘C with
primary mouse anti-human antibodies against NT-labeled
residues (diluted 1 : 300, Santa Cruz Biotechnology, clone sc-
32757, USA), previously validated for human samples [13].
The secondary antibody, horseradish peroxidase, and 3,3󸀠-
diaminobenzidine (DAB) were provided by the commercial
kit (Dako LSAB, Germany). In the last step, sections were
weakly counterstained with Harry’s hematoxylin (Merck).
For each case, negative controls were performed on serial
sections by omitting the primary antibody incubation step.
The intensity and localization of the immunoreactivity were
examinedwith a photomicroscope (LeicaDM2500 and Leica
DFC280, Leica, Germany).
2.3. Sample Processing for Determining the Tissue Oxida-
tive Status. Frozen tissue samples were thawed, precisely
weighted, and homogenized in sterile saline phosphate buffer
10mM pH 7.4, at a final concentration of 100mg tissue/mL.
The mixture was centrifuged at 5000×g, 4∘C during 10
minutes. Supernatants were collected and kept in ice bath
until analysis. All described methods used this concentration
of tissue homogenate, except when some specific dilution is
highlighted. Heparinized blood samples were centrifuged at
1500×g, 4∘C during 5 minutes. Plasma samples were sepa-
rated for further analysis. All measurements were conducted
at the same day of sample processing.
2.4.Measurement of Tissue Lipoperoxidation byHigh-Sensitiv-
ity Chemiluminescence. Lipoperoxidation of adjacent and
tumoral tissue was evaluated as previously published, with
some adaptations [14]. Aliquots of 250 𝜇L of tissue homo-
genate (100mg/mL)were added to 750 𝜇L of saline phosphate
buffer 10mM pH 7.4, with addition of 10 𝜇L of t-butyl 3mM
solution. For plasma analysis, 200𝜇L of sample was mixed
with 780𝜇L of saline phosphate buffer 10mM pH 7.4, with
addition of 20𝜇L of t-butyl 3mM solution. Readings were
carried out in a Glomax luminometer (Glomax, Promega).
The results were expressed as relative light units (RLU) and
the entire curve profile was used as indicator of lipoperoxida-
tion. The area under the curve (AUC) was obtained by area
integration.
2.5. Determination of LipidHydroperoxide Level by the Ferrous
Oxidation-Xylenol Orange (FOX)Method. Lipid hydroperox-
ide concentrations in samples were estimated by the FOX
method as published by Victorino et al. [15]. Plasma or tissue
homogenate aliquots of 50𝜇L were mixed with 50𝜇L of FOX
reagent. Samples were incubated for 30 minutes in the dark
at room temperature and the absorbance of the supernatant
wasmeasured at 550 nm and the results were expressed as 𝜇M
hydroperoxide/mg tissue.
2.6. Carbonyl Content and Antimyeloperoxidase Determina-
tion. Carbonyl content wasmeasured as estimate of oxidative
injury in proteins [16]. Tissue homogenate or plasma aliquots
of 200𝜇L were added in 2 tubes. Test tubes received 1mL
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of dinitrophenylhydrazine (DNPH) 10mM and blank tubes
received 1mL of HCL 2.5M. Tubes were incubated during
1 hour in ice bath. After that, samples were successively
incubated with 1.25mL of trichloric acetic acid 20% and
10% in ice bath during 20 minutes each, with centrifuga-
tion between incubations (1400×g/15 minutes). Supernatants
were discarded and pellets were twice treated with 1mL of
an ethanol/water solution (1 : 1). The final precipitates were
dissolved in 1mL of guanidine 6M and were left for 24 hours
at 37∘C. Carbonyl content was calculated by obtaining the
spectra at 355–390 nm of DNPH-treated samples, employing
one blank tube for each test. The obtained peaks were
employed to calculate carbonyl concentration using a molar
extinction coefficient of 22M−1cm−1. Results were expressed
as nmol/mL/mg tissue. Myeloperoxidase was detected by a
commercial ELISA kit following manufacturer’s instructions
(IBL International, Germany), and the data were expressed as
U anti-MPO/mL.
2.7. Total Radical-Trapping Antioxidant Parameter (TRAP).
TRAP was measured in pure breast tissue homogenates
(100mg/mL) or plasma samples (diluted 1 : 50). For TRAP
calculation, the induction time of the sample (time for which
the sample antioxidants can inhibit the ABAP action) was
compared to that of the standard antioxidant (trolox) and
expressed as 𝜇M trolox/g tissue [17].
2.8. Evaluation of Nitrite as Estimate of Nitric Oxide (NO)
Levels. NO was estimated by measuring nitrite as previously
described [18]. Homogenate or plasma samples (60 𝜇L) were
deproteinized, and the supernatants were recovered and
incubated with cadmium granules. After 10 minutes, the
Griess reagent (Sigma) was added to 200 𝜇L of the super-
natants, and the reactions were incubated for 10 minutes at
room temperature. The absorbance was read at 550 nm using
a standard microplate reader (Multiskan EX, LabSystems,
Minnesota, USA). The final results were expressed as 𝜇M
nitrite/mg tissue.
2.9. Estimation of MDA Levels by High-Performance Liq-
uid Chromatography (HPLC). MDA determinations were
made using equipment HPLC-20AT Shimadzu equipped
with a LC20AT pump and SPDM20A UV, diode array
absorbance detector employing a C18 reverse phase column,
as described by [15]. Aliquots of 160 𝜇L of plasma samples,
tissue homogenate, or standard solution reacted with 100𝜇L
of 0.5M perchloric acid. Samples were centrifuged for 5
minutes, 5000×g at 4∘C. About 180 𝜇L of supernatant was
recovered to react with 100 𝜇L of thiobarbituric acid for 30
minutes, at 95∘C, and transferred to ice bath to stop reaction.
100 𝜇L of 1M NaH2PO4, pH 7.0, was added to stabilize
sample pH. Further, samples were centrifuged for 10minutes,
5000×g at 4∘C. Mobile phase was composed of 65% 50mM
KH2PO4 buffer, pH 7.0, and 35% methanol HPLC grade.
Readings were executed at 535 nm during 12 minutes with
isocratic flow of 0.8mL/minute and results were expressed as
MDA peak height.
Table 1: Clinicopathological characterization of patients.
Number of patients 𝑁 = 50
Mean age at diagnosis (range, years) 53.8 (31–77)
Histological type
Ductal infiltrative carcinoma 100%
Histological grade
1 or 2 70%
3 30%
TNM classification
I/II stage 83.3%
III stage 16.7%
IV stage None
Tumor size
Mean (range) cm 2.88 (0.9–5)
Mean BMI (kg/m2) 24.2
TNM = tumor-node-metastasis classification, BMI= body mass index.
2.10. Homocysteine and TNF-𝛼 Levels. Homocysteine (Axis-
Shield Diagnostics, Abbott Diagnostics Division, UK) and
TNF-𝛼 levels (e-Bioscience, USA) were determined in
aliquots of 200𝜇L of plasma or tissue homogenates by using
commercial kits. Homocysteine was expressed as 𝜇mol/L and
TNF-𝛼 as pg/mL.
2.11. Statistical Analysis. All analyses were conducted in trip-
licate sets. Statistical analysis was performed using GraphPad
Prism 5.0, Microsoft Office Excel 2007, and OriginLab 7.5
software. Results were expressed as arithmetic means and
errors of the means. Differences among groups were assessed
by two-way analysis of variance (ANOVA)with post hoc Bon-
ferroni’s test for the lipid peroxidation curves and by Student’s
paired 𝑡-test for the other parametric parameters. Nonpara-
metric data was analyzed by Mann-Whitney or Wilcoxon
matched-pairs tests. Correlations among parameters in
plasma and tumoral tissuewere also performedusingPearson
or Spearman tests. All data were checked using the Grubbs
test (GraphPad Quickcalcs) to eliminate significant outliers
(𝑝 < 0.05). 𝑝 < 0.05 was considered statistically significant.
3. Results
Table 1 shows the clinicopathological characterization of the
50 patients enrolled in this study. The mean age at diagnosis
was 53.8 years, ranging from 31 to 77 years. Most of tumors
presented histological grade 2 and the mean tumor size was
2.9 cm. Regarding tumor subtype, a prevalence of luminal
tumors was found (30% of patients presented luminal A
tumors, 20% were triple negative, 26.6% had HER2 enriched,
and 23.4% were typed as luminal B). Most women presented
local or locoregional disease (TNM I/II, 83.3%; TNM III,
16.7%), without any presence of distant metastasis. None
of the included women were overweight/obese at diagnosis.
The number of patients did not allow dividing the groups
regarding the molecular subtype.
Aiming at characterizing the redox status of adjacent and
tumoral breast tissue samples, we performed the analysis of
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Figure 1: Lipid peroxidation profile of mammary adjacent tissue (MA) and tumoral tissue (TU).
some markers of oxidative damage in lipids and proteins.
Figure 1 shows the lipid peroxidation profile determined
by high-sensitivity chemiluminescence. This method allows
identifying the oxidative damage of RS on lipidic compo-
nents located at the plasmatic membrane. As shown, the
adjacentmammary tissue presented higher lipid peroxidation
status than the tumoral tissue (𝑝 < 0.0001). Other lipid
peroxidation-derived metabolites did not vary (FOX and
MDA levels, Figures 2(a) and 2(b)).
Elevated homocysteine levels (from 7.26 ± 0.31 𝜇M/
100mg tissue in adjacent breast to 9.49 ± 1.08 𝜇M/100mg
tissue in tumoral tissue, 𝑝 = 0.0221, Figure 2(c)) were
found in the tumoral tissue when compared to the adjacent
mammary breast. Antioxidant capacity of tumoral tissue
was significantly higher than the adjacent breast (5532 ±
1041 nM trolox/g tissue in adjacent breast and 9181 ±
1041 nM trolox/g tissue in tumor, 𝑝 = 0.0068, Figure 2(d)).
Tumor samples displayed increased TNF-𝛼 levels (239.8±
13.07 pg/mL of homogenate in adjacent breast and 418.1 ±
19.6 pg/mL of homogenate in tumoral tissue, 𝑝 < 0.001,
Figure 3(a)) and NO (4.64 ± 0.32 𝜇M/mg tissue in adjacent
breast and 6.89 ± 0.32 𝜇M/mg tissue in tumoral tissue, 𝑝 <
0.001, Figure 3(b)).
The protein-induced oxidative modifications are rep-
resented in Figure 4. All tumor samples presented mod-
erate/intense labeling for nitrotyrosine labeling, suggesting
a prooxidant role for NO in breast cancer (Figure 4(a)).
High carbonyl content (from 12.33±2.56 nmol/100mg tissue
in adjacent breast to 22.39 ± 3.95 nmol/100mg tissue in
tumoral tissue, 𝑝 = 0.0274, Figure 4(b)) was found in
breast tissue. Anti-MPO levels did not vary between groups
(2.3 ± 0.35U/100mg tissue in adjacent breast and 1.83 ±
0.44U/100mg tissue in tumoral tissue, 𝑝 = 0.6129). Semi-
quantitative analysis of nitrotyrosine (Figure 4(d)) showed
augmented levels in TU samples when compared to the
adjacent normal breast (0.625 ± 0.18 arbitrary unities in MA
samples and 2.125 ± 0.226 arbitrary unities in TU samples,
𝑝 = 0.0025).
We further performed Spearman analysis to investigate
whether there was some correlation between the oxidative
status of tumors and its respective plasma obtained from
the same patient (Table 2). All parameters were compared.
Significant positive correlations were found with plasmatic
versus tumoral TNF-𝛼 (𝑝 < 0.001), tumoral nitrotyrosine
versus plasmatic NO (𝑝 = 0.0456), and plasmatic versus
tumoral carbonyl contents (𝑝 = 0.0302).
4. Discussion
It is known that oxidative stress is active during the car-
cinogenic process and correlates with disease prognosis in
breast cancer patients [19, 20]. In spite of that, this is
the first characterization of the oxidative status of human
tumor samples in comparison with matched nontumoral
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Figure 2: Oxidative stress markers in the mammary adjacent tissue (MA) and the tumoral tissue (TU).
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Figure 3: Tumor necrosis factor-alpha (TNF-𝛼) and nitrite as estimate of nitric oxide levels (NO) from mammary adjacent tissue (MA) and
tumoral tissue (TU).
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Figure 4: Protein-induced oxidative modifications and MPO detection in mammary adjacent tissue (MA) and tumoral tissue (TU).
adjacent mammary tissue. Our findings indicate that the
breast tumor presents a variable oxidative profile. There was
reduced oxidative stress as demonstrated by reduced lipid
peroxidative reaction, revealed by the decrease of chemilu-
minescence and MDA levels and increased total antioxidant
capacity (TRAP). Contrarily, nitrosative stress increased as
nitrotyrosine labeling and NO was shown to be augmented
in tumoral tissue with significant correlation between them.
Protein oxidation also was elevated in tumoral tissue
possibly as a consequence of nitrosative stress. Our results
showing high levels of TNF besides increased levels of
NO and nitrotyrosine suggest a possible cross talk between
nitrosative stress and inflammatory mediators in tumor
tissue. This cross talk is enforced by the significant corre-
lation between TNF-𝛼, NO, nitrotyrosine, and the carbonyl
content between tumor and its matched plasma sample.
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Table 2: Spearman’s correlations among the levels of oxidative
parameters in plasma and plasma matched tumoral tissue.
Plasma versus tumor 𝑟 value 𝑝 value
TNF-𝛼 0.8322 𝑝 < 0.001∗
NO × nitrotyrosine 0.7771 𝑝 = 0.0456∗
Carbonyl content 0.7082 𝑝 = 0.0302∗
TRAP −0.09790 𝑝 = 0.7621
Homocysteine 0.2562 𝑝 = 0.5680
MDA 0.5691 𝑝 = 0.8954
Anti-MPO 0.6598 𝑝 = 0.6977
Lipid peroxidation 0.5870 𝑝 = 0.2314
NO 0.5477 𝑝 = 0.7894
TNF-𝛼 = tumor necrosis factor-alpha, TRAP = total antioxidant capacity,
MDA = malondialdehyde, and MPO = myeloperoxidase.
∗ indicates significant statistical difference (𝑝 < 0.05).
The mammary tissue presents a large content of adipocytes,
which provides abundant feedstock for the occurrence of
lipid peroxidation reactions. Polyunsaturated fatty acids that
contain two or more double bonds are more susceptible to
peroxidation [21]. Several RS may abstract the first hydrogen
atom to produce a lipid peroxyl radical [22]. In this context,
we first evaluated the lipid peroxidation chain by using a
chemiluminescence-based analysis. Here, the initiation step
is characterized by the ascending part of the curve, which
is dependent on the antioxidant content of the tissue [23].
The analysis of this initial reaction revealed that the lipids
from adjacent nontumoral tissue were more oxidized than
the lipidic content of tumor samples. The occurrence of
reduced lipid peroxidation in the breast cancer environment
has been reported in nipple aspirate fluids, suggesting a role
for the downregulation of lipid peroxidation products in
carcinogenesis [24]. Low lipid peroxidation activates several
redox signaling pathways that recruit antioxidant induction
from the organism to the site of increasing RS production and
this configures a survival adaptation [25, 26].
In association with the reduced lipid peroxidation profile
of tumors, we further found unaltered levels of lipid peroxi-
dation products in tumor samples, as hydroperoxides (FOX)
and malondialdehyde (MDA), suggesting that other low
molecular weight substances may affect the lipoperoxidative
status of cells. These findings indicate that, in some instance,
tumors are protected against lipid peroxidation, potentially
by accumulating membrane and intracellular antioxidants
that neutralize this process. This fact was corroborated by
the enhanced antioxidant capacity detected in tumor samples
when compared to normal adjacent tissue, which explains the
reduced lipid peroxidation chain observed in breast tumors.
Therefore, high antioxidant content inside breast tumors
may be able to retard the initiation of lipid peroxidation
process, which may have a regulatory role in cell adaptation
to oxidative changes.
In spite of the enhanced antioxidant capacity of tumors,
we found significant augmented protein carbonylation in the
tumoral tissue (but not in the adjacent mammary breast).
The carbonylation reaction is an irreversible posttranslational
modification that occurred in protein structure that results
from the reaction between amino acid residues with the low
molecular weight aldehydes generated during the lipid per-
oxidation process [27–30] and it is reported as an oxidative
marker locally produced in the cancerous breast [31].
We further detected increased homocysteine levels in
breast tumors, suggesting the attack of thiol residues by
RS originated in tumor microenvironment. Homocysteine
regulates cell cycle, apoptosis, and oxidative stress responses
[32]. A direct relationship between high homocysteine and
enhanced carbonyl content has been demonstrated [33], indi-
cating that the augmented carbonylation of tumor proteins
can be induced by high homocysteine concentration.
In cancer cells, enhanced activity of proinflammatory
cytokines leads to RS production [27]. A recent study of
nipple aspirate fluids obtained from patients with breast
cancer indicated that high levels of cytokines, as TNF-
𝛼, are concomitant with augmented protein carbonylation
[34] and correlated with elevated systemic homocysteine
[35], corroborating the present findings in tumor samples.
Therefore, enhanced carbonyl content, homocysteine, and
TNF-𝛼 level seem to comprise a network communicating
with each other in the breast cancer microenvironment.
The prooxidative status found here in the tumoral tissue
was probably sustained by its proinflammatory nature, as
shown by TNF-𝛼 and NO levels in tumor samples. NO is
a multifunctional molecule in cancer. Our data indicate a
nitrosative function for this molecule inside breast tumor,
as nitrotyrosine was found only in the tumor analysis and
not detected in the nontumorous counterpart. In addition,
the TNF-driven pathway is constitutively activated in breast
cancer [8], inducing NO and increasing [36] and modulating
oxidative stress in breast cancer cells [37]. Our previous
publications have demonstrated that these patients carry-
ing breast tumors present a variety of oxidative plasmatic
modifications, and we have questioned if this fact could be
related with tumor oxidative status. Therefore, we performed
a correlation analysis aiming to understand the putative
association between levels of oxidative stress parameters in
plasma versus tumoral tissue. We have found significant
correlations between plasmatic versus tumoral levels of TNF-
𝛼, NO/nitrotyrosine, and carbonyl content. Altogether, these
data support that the systemic prooxidative status reported
for several studies in breast cancer patients may be correlated
with tumor-driven inflammation.
A recent study from our group [16] has demonstrated
that the presence of the primary tumor mass is determinant
for the sustained proinflammatory systemic status found
in women with breast cancer, which included high NO,
enhanced oxidative stress, and augmented TNF-𝛼.Therefore,
in spite of the reduced size of the tumor mass, it seems that
the breast tumor microenvironment (cancer cells, infiltrated
macrophages, and endothelial cells) is endowedwith an enor-
mous capability to promote profound modifications in the
host organism, resulting in the persistent inflammatory status
provoked here by TNF-𝛼, NO, and RS production. This fact
cannot be satisfactorily explained by the immune response
against the tumor, since women presenting local breast dis-
ease have systemically established aTh2 immune status [11].
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Another contributing factor to this redox scenario may
be the components of tumor stroma. Tumor-associated
fibroblasts can affect metabolically their adjacent cells, and
cancer cells use the oxidative environment as advantage to
obtain nutrients from the surrounding environment [38].
Further, sustained oxidative stress allows cancer-associated
fibroblasts to become myofibroblasts, which secrete growth
factors and cytokines [39] and yield high ROS generation
[40]. This vicious cycle may also affect distant mammary
cells by propagating the prooxidant signaling in a paracrine
manner, which helps to explain the altered oxidative profile
observed here in the distant mammary adjacent tissue.
In conclusion, this set of redox alterations found in breast
tumors seems to be necessary to ensure the hallmarks of
cancer biology, since RS have been implicated in oncogene
activation, genomic instability, chemotherapy resistance, and
the metastatic process [5]. Furthermore, it is known that
enhanced antioxidant capacity has been strongly associated
as an innate tumoral mechanism for acquiring chemoresis-
tance [41]. The presented data point to the existence of a cor-
relation between tumor proinflammatorymediators and their
circulating levels, suggesting that the tumormay be a putative
source that stimulates the onset of such substances in blood.
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